[Molecular Formula] C187H282N50O60S
[CAS No.] 141732-76-5
Description of Exenatide Acetate :
Water Content(Karl Fischer) :≤5.0%
Acetate Content(by HPLC) :≤12.0%
Amino Acid Composition :±10% of theoretical
Purity (by HPLC) :≥98.0%
Single Impurity(by HPLC) :≤1.0%
Peptide Content(by %N ) :≥80%
Assay(By Anhydrous, Acetic Acid-free ) :95.0~105.0%
Bacterial Endotoxins :≤5EU/mg
Pharmacologic class: Incretin mimetic
Therapeutic class: Hypoglycemic
Pregnancy risk category C
Exenatide acetate is a sort of white powder.Acetate Content(by HPLC) :≤12.0%
Amino Acid Composition :±10% of theoretical
Purity (by HPLC) :≥98.0%
Single Impurity(by HPLC) :≤1.0%
Peptide Content(by %N ) :≥80%
Assay(By Anhydrous, Acetic Acid-free ) :95.0~105.0%
Bacterial Endotoxins :≤5EU/mg
Pharmacologic class: Incretin mimetic
Therapeutic class: Hypoglycemic
Pregnancy risk category C
Exenatide (INN, marketed as Byetta, Bydureon) is a medication approved in April 2005 for the treatment of diabetes mellitus type 2. It belongs to the group of incretin mimetics and is manufactured by Amylin Pharmaceuticals Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27th, 2012 under the trademark, Bydureon.
Read More: buy exenatide acetate
No comments:
Post a Comment